RxDoctor Payments Data

Karen Schogel, MD

Internal Medicine · Cranberry Twp, PANPI 1942294228

Payments from drug & device makers

$12,352in general payments, 2019–2025

Across 789 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$1K
  • GSK$1K
  • AstraZeneca$764
  • Amgen$693
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$12,09198%
  • Education$2142%
  • Gifts$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)113$1,784
Novo Nordisk95$1,362
Pfizer91$1,175
GSK68$1,056
AstraZeneca(2 entities)45$764
Amgen(2 entities)45$693
Boehringer Ingelheim40$631
Lilly USA, LLC36$542
Johnson & Johnson31$444
E.r. Squibb & Sons, L.L.C.18$372
Abbott17$310
Merck18$297
Astellas Pharma US Inc9$251
Amarin Pharma, Inc.14$210
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$203
Currax Pharmaceuticals LLC14$195
Daiichi Sankyo Inc.9$157
Bayer9$144
Phathom Pharmaceuticals, Inc.7$121
Takeda Pharmaceuticals U.S.A., Inc.12$102
Axsome Therapeutics, Inc.4$87
Sanofi-aventis U.S. LLC6$85
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$76
Biogen4$71
Ironwood Pharmaceuticals, Inc4$63
Inari Medical, Inc.2$57
Kowa Pharmaceuticals America, Inc.4$57
Shield Therapeutics Inc3$56
Amneal Pharmaceuticals LLC3$56
Sanofi Pasteur Inc.3$53
Esperion Therapeutics, Inc.3$52
Biohaven Pharmaceutical Holding Company Ltd.2$51
Kaleo, Inc.3$48
Tosoh Bioscience, Inc.1$47
Genentech USA, Inc.3$42
Biohaven Pharmaceuticals, Inc.2$39
CSL Behring2$37
Mylan Specialty L.p.2$36
Novartis2$35
Shire North American Group Inc2$31
Cequr Corporation1$31
Paratek Pharmaceuticals, Inc.2$29
Teva Pharmaceuticals USA, Inc.2$29
Aytu Biopharma, Inc.2$27
Upsher-smith Laboratories LLC1$25
Photonicare Inc1$23
Eisai Inc.2$23
Bristol Myers Squibb1$23
Vertex1$23
Organogenesis Inc.1$22
Appliedvr Inc1$21
Hikma Pharmaceuticals USA1$20
Otsuka America Pharmaceutical, Inc.1$19
Exact Sciences1$18
Ultragenyx Pharmaceutical Inc.1$18
Sumitomo Pharma America, Inc.1$17
Medicomp Inc1$16
Avanir Pharmaceuticals, Inc.1$15
Vivus LLC1$13
Melinta Therapeutics, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,352 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$143,877
Medicare patients
311
Services billed
3,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$85,219
JardianceEmpagliflozin70$82,236
OzempicSemaglutide35$58,289
OxycontinOxycodone Hcl24$31,065
RybelsusSemaglutide13$27,835
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$26,517
FarxigaDapagliflozin Propanediol29$26,480
MounjaroTirzepatide15$17,821
SynjardyEmpagliflozin/Metformin Hcl12$12,598
Breo ElliptaFluticasone/Vilanterol28$10,727
EntrestoSacubitril/Valsartan14$10,499
ShingrixVaricella-Zoster Ge/As01b/Pf38$8,446
Janumet XrSitagliptin Phos/Metformin Hcl12$6,762
LinzessLinaclotide12$5,920
Icosapent Ethyl16$4,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$631$94,83382 claims
PfizerEliquis, Paxlovid$1,175$86,648111 claims
Novo NordiskOzempic, Rybelsus$1,362$86,12448 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$1,056$45,69091 claims
AstraZenecaFarxiga$764$26,48029 claims
Lilly USA, LLCMounjaro$542$17,82115 claims
NovartisEntresto$35$10,49914 claims
AbbVieLinzess, Synthroid$1,784$8,92553 claims
MerckJanumet Xr$297$6,76212 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$56$3,391317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Cranberry Twp

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →